Evidence map›Paper›PMID 27159171›Full record

ArticleBone marrow transplantation2016

Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.

H J Im, K N Koh, J K Suh, S W Lee, E S Choi, S Jang, S W Kwon, C-J Park, J J Seo

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

H J ImDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
K N KohDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
J K SuhDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
S W LeeDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
E S ChoiDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
S JangDepartment of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
S W KwonDepartment of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
C-J ParkDepartment of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
J J SeoDepartment of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
University of Ulsan · KRUlsan College · KRAsan Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Between 2012 and 2015, 42 pediatric patients underwent haploidentical hematopoietic cell transplantation using an αβ(+) T-cell-depleted graft with targeted αβ cells at 1-5 × 10(5)/kg by add-back; 31 had hematologic malignancy (HM), 8 had non-malignant disease (NM) and 3 had solid tumors. All patients received uniform reduced-intensity conditioning with fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin and low-dose TBI. All 42 patients achieved neutrophil engraftment at a median of 10 days. The cumulative incidences (CIs) of ⩾grade II and ⩾grade III acute GvHD were 31±7.1% (SE) and 12±5.0%, respectively, and 1-year CI of chronic GvHD was 15±5.8%. One patient died of CMV pneumonia, leading to transplant-related mortality (TRM) of 2.6±2.5%. Sixteen patients relapsed and 11 died of disease. At a median follow-up of 19 months (range, 5-43 months), the estimated 2-year event-free survival for NM and HM were 88±11.7 and 50±10.1%, respectively. Our study demonstrated that haploidentical hematopoietic cell transplantation after ex vivo depletion of αβ(+) T cells with targeted dose noticeably reduced the graft failure rate and TRM in pediatric patients and could be applied to patients lacking a suitable related or unrelated donor.

Indexed as

AdolescentAntilymphocyte SerumChildChild, PreschoolCyclophosphamideFemaleFollow-Up StudiesGraft vs Host DiseaseHematologic NeoplasmsHumansInfantLymphocyte DepletionMaleNeoplasmsReceptors, Antigen, T-Cell, alpha-betaSurvival AnalysisAntilymphocyte SerumCyclophosphamidefludarabineReceptors, Antigen, T-Cell, alpha-betaVidarabine

Identifiers

PMID27159171
OpenAlexW2346219996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.